Brands
Brands have to take a back seat and tell human interest stories
MUMBAI: At a time when the world is moving towards the digital medium, can advertising be far behind?
Indeed, the last couple of years have seen several brands and agencies falling back on this space to reach out to their consumers.
D&AD’s CEO Tim Lindsay and president & Dare CD Laura Jordan Bambach who are in the country to address the forthcoming seminar (organised by Kyoorius) on Building Brands via Digital Media, shared some valuable insights on the subject with indiantelevision.com.
On the fast blurring line between traditional and digital advertising in India, Tim quips: “Probably there are other markets which are further ahead when it comes to digital; and this is simply to do with the penetration of tablets, laptops and smart phones. Mobile is highly developed in this country and will only amplify. Therefore, digital advertising and marketing will develop in a separate way in India.”
Still to recover from jet lag, Laura adds: “It is quite an exciting time and I can see the behaviour change and there is a more digital approach in various campaigns; which is more worldwide, but it is there here as well. The change in advertising message is becoming more purposeful.”
Speaking about the trend of viral videos, Laura says they would work better if people had an interesting story to tell rather than the brand putting forth its message. “The brand has to take a back seat and tell a human interest story. Not all viral campaigns are good, there are many bad ones as well because they don’t tell you the story you want to hear,” she says, pointing out that videos which are entertaining, funny and have a human angle are likely to click with the viewers.
Also the co-founder of SheSays, an international volunteer organisation encouraging women to take up digital creative careers, Laura feels things are changing now as more and more women are not only entering the field but also reaching high positions. “There are a quite a few women in the higher ranks and the things are looking up in India as well,” she says.
Asked to point out the two important advertising trends of 2013, Tim talks about ads and campaigns having moved more towards story-telling apart from the increased engagement of people through branded content and added efforts by companies to take their CSR activities more seriously. He cites the example of Unilever’s latest Project Sunlight (Unilevers Project Sunlight promises a brighter future) . “In India, HUL’s Lifebuoy campaigns have been very successful. Be it the village one or the stamped rotis,” he says.
In the coming year, Tim feels there will be more acquisitions including digital acquisitions of smaller agencies which will only serve to increase their credibility and sustainability.
Both Tim and Laura feel that hereon, the digital space is only set for a further boom, with agencies milking the medium to reach out to as many people as possible.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
